Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
99mTc-CS
- Development stage
- Unknown
- Lead developer
- Medical University of Vienna
- Modality
- Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
99mTc-CS is an investigational diagnostic radiopharmaceutical consisting of chondroitin sulfate (CS) radiolabeled with the gamma-emitting isotope technetium-99m (99mTc). Developed by researchers at the Medical University of Vienna, it is designed for the non-invasive imaging of articular cartilage using scintigraphy or SPECT. The tracer exhibits chondrotropism, accumulating in the proteoglycan-rich extracellular matrix and chondrocytes of articular cartilage, either through adsorption or as a substrate for proteoglycan synthesis. It is primarily being evaluated for the detection and quantification of cartilage degeneration in patients with osteoarthritis, providing a functional imaging alternative or complement to MRI.
- Other names
- 99mTc-labeled chondroitin sulfatetechnetium-99m chondroitin sulfatetechnetium99m chondroitin sulfatetechnetium 99m chondroitin sulfate
Beyond the preview
Go deeper on 99mTc-CS.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 99mTc-CS.